Tempo Scan Pacific Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Tempo Scan Pacific has been growing earnings at an average annual rate of 18%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 5% per year. Tempo Scan Pacific's return on equity is 16.3%, and it has net margins of 9.7%.
Anahtar bilgiler
18.0%
Kazanç büyüme oranı
17.9%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 20.4% |
| Gelir büyüme oranı | 5.0% |
| Özkaynak getirisi | 16.3% |
| Net Marj | 9.7% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Tempo Scan Pacific nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 13,503,682 | 1,307,959 | 3,309,043 | 0 |
| 30 Jun 24 | 13,410,111 | 1,305,642 | 3,295,566 | 0 |
| 31 Mar 24 | 13,327,850 | 1,016,103 | 3,437,309 | 0 |
| 31 Dec 23 | 13,119,785 | 1,177,432 | 3,417,748 | 0 |
| 30 Sep 23 | 12,930,978 | 1,413,211 | 3,519,904 | 0 |
| 30 Jun 23 | 12,799,616 | 1,315,609 | 3,577,123 | 0 |
| 31 Mar 23 | 12,515,628 | 1,299,873 | 3,529,528 | 0 |
| 31 Dec 22 | 12,254,369 | 1,001,628 | 3,454,079 | 0 |
| 30 Sep 22 | 11,979,281 | 818,701 | 3,096,147 | 0 |
| 30 Jun 22 | 11,690,793 | 793,249 | 3,039,198 | 0 |
| 31 Mar 22 | 11,463,255 | 807,365 | 2,970,760 | 0 |
| 31 Dec 21 | 11,234,443 | 823,768 | 2,892,475 | 0 |
| 30 Sep 21 | 11,221,801 | 837,814 | 2,819,374 | 0 |
| 30 Jun 21 | 11,098,709 | 826,410 | 2,794,638 | 0 |
| 31 Mar 21 | 10,946,622 | 790,636 | 2,675,396 | 0 |
| 31 Dec 20 | 10,968,402 | 787,803 | 2,772,892 | 0 |
| 30 Sep 20 | 10,913,436 | 633,438 | 2,982,544 | 0 |
| 30 Jun 20 | 10,988,140 | 594,286 | 3,154,610 | 0 |
| 31 Mar 20 | 11,054,774 | 635,033 | 3,357,757 | 0 |
| 31 Dec 19 | 10,993,842 | 554,263 | 3,384,658 | 0 |
| 30 Sep 19 | 10,838,260 | 506,498 | 3,382,474 | 0 |
| 30 Jun 19 | 10,645,094 | 503,850 | 3,321,810 | 0 |
| 31 Mar 19 | 10,409,876 | 511,785 | 3,235,336 | 0 |
| 31 Dec 18 | 10,088,119 | 512,029 | 3,173,692 | 0 |
| 30 Sep 18 | 9,953,788 | 524,501 | 3,115,288 | 0 |
| 30 Jun 18 | 9,771,237 | 544,322 | 3,080,273 | 0 |
| 31 Mar 18 | 9,605,084 | 539,972 | 3,048,925 | 0 |
| 31 Dec 17 | 9,565,462 | 543,804 | 3,015,024 | 0 |
| 30 Sep 17 | 9,367,620 | 518,924 | 3,009,341 | 0 |
| 30 Jun 17 | 9,048,306 | 534,918 | 2,846,219 | 0 |
| 31 Mar 17 | 9,282,651 | 537,987 | 2,880,653 | 0 |
| 31 Dec 16 | 9,138,239 | 536,274 | 2,810,042 | 0 |
| 30 Sep 16 | 8,974,716 | 461,111 | 2,713,811 | 0 |
| 30 Jun 16 | 8,863,164 | 488,536 | 2,670,123 | 0 |
| 31 Mar 16 | 8,440,155 | 495,765 | 2,520,766 | 0 |
| 31 Dec 15 | 8,181,482 | 521,959 | 2,436,500 | 0 |
| 30 Sep 15 | 8,042,806 | 551,874 | 2,492,578 | 0 |
| 30 Jun 15 | 7,897,221 | 539,332 | 2,464,054 | 0 |
| 31 Mar 15 | 7,753,038 | 559,450 | 2,392,204 | 0 |
| 31 Dec 14 | 7,512,115 | 580,870 | 2,279,817 | 0 |
| 30 Sep 14 | 7,314,777 | 608,484 | 2,219,797 | 0 |
| 30 Jun 14 | 7,145,508 | 619,972 | 2,117,326 | 0 |
| 31 Mar 14 | 6,963,447 | 652,441 | 2,048,661 | 0 |
| 31 Dec 13 | 6,854,889 | 634,623 | 2,049,177 | 0 |
Kaliteli Kazançlar: TSPC has high quality earnings.
Büyüyen Kar Marjı: TSPC's current net profit margins (9.7%) are lower than last year (10.9%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: TSPC's earnings have grown by 18% per year over the past 5 years.
Büyüme Hızlandırma: TSPC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: TSPC had negative earnings growth (-7.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4%).
Özkaynak Getirisi
Yüksek ROE: TSPC's Return on Equity (16.3%) is considered low.